-
Affimed N.V. NASDAQ:AFMD Affimed is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company's proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK platform predictably generates customized innate cell engager (ICE®) molecules, which use patients' immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE®. Headquartered in Heidelberg, Germany, with offices in New York, New York, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients' lives.
Location: | Website: www.affimed.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
37.3M
Cash
34.45M
Avg Qtr Burn
-21.01M
Short % of Float
7.54%
Insider Ownership
6.01%
Institutional Own.
36.99%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
AFM13 (Acimtamig) + AB-101 Details Cancer, Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphomas | Phase 2 Data readout | |
AFM24 (tumor target EGFR) w/ SNK01 & atezolizumab Details Solid tumor/s, Cancer, Non-small cell lung carcinoma | Phase 2 Update | |
AFM13 (Acimtamig)+ cbNK cells Details Cancer, Non-Hodgkin lymphoma | Phase 2 Update | |
AFM13 (Acimtamig) Details Peripheral T cell cancer , Cancer | Phase 2 Initiation | |
AFM28 Details Cancer, Blood cancer, Leukemia, Acute myeloid leukemia | Phase 1 Data readout | |
AFM24 (tumor target EGFR) Monotherapy Details Solid tumor/s, Cancer, Non-small cell lung carcinoma, Colorectal cancer | Failed Discontinued | |
RO7297089 (formerly AFM26) Details Multiple myeloma, Cancer | Failed Discontinued |